Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like Struggling Teva Loses Top R&D Exec To Eli Lilly, Novartis AG-Backed Cavion August 14, 2017 <b>VenatoRx Pharma</b> Banks $42 Million to Advance Antibiotics Pipeline July 24, 2017 Why Pfizer May Need Another Big M&A for Growth May 16, 2017